Back
ESC Premium Access

Guidelines and the role of non-statin therapies for ASCVD reduction in high risk patients - Addressing statin intolerance and poor target LDL-C goal attainment

Session: PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease
Topic: Lipids
Speaker: Professor J. Jukema (Leiden, NL)
Sponsored by Sanofi US and Regeneron Pharmaceuticals
Event: ESC Congress 2018

Congress Presentation

0

About the speaker

Professor J Wouter Jukema

Leiden University Medical Center, Leiden (Netherlands (The))
16 presentations
0 follower

4 more presentations in this session

Chairman’s welcome and introduction: the mandate for improving residual cardiovascular disease risk reduction in patients with adversely elevated LDL-C

Speaker: Professor D. Bhatt (New York City, US)

Access
Slides
Video
0
Thumbnail

What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us?

Speaker: Professor P. Steg (Paris, FR)

Access
Slides
Video
0
Thumbnail

Getting real world and “hands on” in patients with elevated LDL-C and high risk features for atherosclerotic cardiovascular disease — Case management sessions.

Speaker: Professor D. Bhatt (New York City, US)

Access
Slides
Video
0
Thumbnail

Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.

Speaker: Professor D. Bhatt (New York City, US)

Access
0
Thumbnail

Access the full session

PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

Speakers: Professor J. Jukema, Professor D. Bhatt, Professor P. Steg, Professor D. Bhatt, Professor D. Bhatt
Access
0
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk